Background: To evaluate the large-scale feasibility and usefulness of geriatric screening and assessment in clinical oncology practice by assessing the impact on the detection of unknown geriatric problems, geriatric interventions and treatment decisions.
introduction About 50% of cancer cases and two-thirds of cancer deaths occur in patients of 65 years and older. Hence, there is a great need to deliver qualitative cancer care for older persons [1] . Older patients with cancer are less likely to be treated according to recommended treatment guidelines and as a consequence, under-treatment may have a strong negative impact on survival [2, 3] . Older patients with cancer represent a very heterogeneous group, where the biological or functional age can differ significantly from chronological age. A Comprehensive Geriatric Assessment (CGA) is considered to be the most appropriate way to obtain a better view on the global health and functional status and reserve capabilities of older individuals. CGA is a multidimensional, interdisciplinary patient evaluation that leads to the identification of the general health status including medical, functional, cognitive, social, nutritional and psychological parameters [4] . There are at least four good reasons for an oncologist to obtain a CGA [5] : (i) CGA has important prognostic information that can be helpful in estimating life expectancy, which is of paramount importance when making treatment decisions; (ii) CGA can predict toxicity or decrease in quality of life (QoL) enabling a more targeted use of preventive measures; (iii) CGA can reveal previously unknown geriatric problems [6] [7] [8] ; (iv) CGA allows targeted interventions, which can improve QoL and compliance to therapy. CGA is therefore recommended in all older patients with cancer, as mentioned in guidelines from the National Cancer Center Network (NCCN) and the International Society of Geriatric Oncology (SIOG) [9] .
Despite all these arguments, CGA is not routinely implemented in clinical care due to several barriers. These include CGA being a time-consuming realization for busy clinicians, the lack of trained staff even in large academic hospitals and poor financial rewarding for performing the CGA by the health insurance system. To focus on frail patients, those who benefit most from CGA, there is an increasing interest in the use of shorter screening tools to detect older persons with a geriatric profile, such as the Flemish Triage Risk Screening Tool (TRST) [10] , Vulnerable Elders Survey-13 (VES-13) [11] , Groningen Frailty Indicator (GFI) [12] or G8 [13, 14] , the latter being validated in older oncology patients in a large French prospective study. It is generally recommended to start with a screening tool and to continue with a CGA only in case of an abnormal screening score.
The present study was set up to assess the feasibility and usefulness of a geriatric screening and assessment in the clinical care of older patients with cancer in academic and non-academic centres in Belgium. The primary objective was to assess how many unknown geriatric problems are detected in older patients with cancer. Other objectives were to assess whether the detection of these problems led to a geriatric intervention and influenced treatment decisions.
patients and methods

patient population
This prospective, multi-centre, non-interventional study was carried out in 10 hospitals in Belgium, including six academic and four non-academic hospitals. Patients 70 years and older with a malignant tumour were included at diagnosis or at disease progression, when a change in therapeutic strategy was considered. Inclusion was limited to six tumour types: breast, colorectal, ovarian, lung, prostate cancer and haematological malignancies. The study was approved by the Ethical Committee of each participating hospital. Informed consent was obtained from all patients or their caregiver.
screening and CGA
In each centre, a trained health care worker (usually a nurse, attached to the oncology and/or geriatric department) was appointed to detect eligible patients and to perform a screening with G8. If G8 (range: 0-17) demonstrated a geriatric profile (score ≤14), a CGA was carried out. The CGA was established in collaboration with the Belgian Society of Gerontology and Geriatric Medicine (BVGG) [15] (supplementary  Table S1 , available at Annals of Oncology online).
The results from the assessment (=screening with/without CGA) were recorded in the medical file of the patient and were delivered (on paper or electronically) to the treating physician, before the (final) treatment decision. It was at the treating physician's discretion to use the information obtained by the assessment when setting up a treatment plan for the older patient.
questionnaire for the treating physician Within a month after the final treatment decision, the trained health care worker contacted the treating physician. The results from the assessment were presented (again) to the treating physician, who completed a questionnaire. This predefined questionnaire contained four questions: (i) were you aware of the assessment results at the time of treatment decision? (ii) Did the assessment reveal any new information for you in the following fields: pain, social problems, functionality, falls, self-perceived fatigue, cognition, depression, nutrition, other? (iii) When you were aware of the results of the assessment, was any action undertaken to deal with the detected problems (=geriatric interventions that would not have been undertaken if assessment was not carried out)? Possible interventions were the involvement of other health care workers or referrals: geriatrician, geriatric liaison team, social worker, occupational therapist, physiotherapist, geriatric day clinic, fall clinic, geronto-psychiatrist, dietician, other. (iv) Did the assessment influence your oncological treatment decision?
statistical analysis
Descriptive statistics were carried out for both continue and discrete values using SAS v9.2. 95% confidence limits were calculated where appropriate. 
patient and clinical characteristics
For participation in the study, 2259 patients were approached. Of these patients, 151 refused to participate and 141 did not meet the inclusion criteria (mostly not being progressive, no invasive tumour diagnosed or primary origin of the tumour different from the six selected tumour types). Written informed consent was given by 1938 patients and 29 caregivers, resulting in 1967 patients included.
Patient characteristics are listed in Table 1 . The median age was 76 (range: 70-96) years, and 64.1% were female. Breast cancer was the most common diagnosis, accounting for 40.5% of the patients, followed by colorectal cancer (21.5%) and haematological malignancies (12.8%). Within the haematological malignancies, non-Hodgkin lymphoma was the most common subtype (49.6%), followed by multiple myeloma (16.7%). At the moment of evaluation, 68.2% had a newly diagnosed cancer, whereas 31.8% had disease progression. Considering comorbidities, 24.9% had score 1 and 38.8% had score ≥2 on the CCI. The most common comorbidities were congestive heart failure (19.4%), peripheral vascular disease (16.2%), secondary malignancy (13.1%) and diabetes mellitus without complications (12.6%). screening and CGA
The results of the geriatric screening are shown in Table 2 . The G8 attributed a geriatric profile with a need for CGA in 70.7%
(n = 1391) of the patients. As shown in Table 3 , the CGA in this group revealed geriatric problems in all domains covered by the CGA. For ADL, 43.5% of the patients were able to 
questionnaire for the treating physician
The results of the questionnaire for the treating physician are shown in Table 4 . A total of 1820 questionnaires (92.5%) was completed by treating physicians (n = 128). In 1115 patients (61.3%), the treating physician indicated being aware of the assessment results at the time of decision making. A learning curve was clearly seen over time: during the first study period (October 2009 to May 2010), 50.8% of treating physicians indicated being aware of the assessment results, increasing to 66% in the second period (June 2010 to December 2010) and 68.6% in the last period (January 2011 to July 2011) (χ 2 trend = 41.5; P < 0.0001). In 51.2% (n = 931) of the total population (n = 1820), the assessment revealed unknown geriatric problems. In the group of patients where the treating physician was aware of the assessment results at the time of decision making (n = 1115), the assessment results led to a geriatric intervention in 286 patients (25.7%). These interventions are related to all assessed domains. For 282 patients (25.3%), the treating physician stated that the assessment results influenced the treatment decision in some way. discussion This is the largest study evaluating the use and impact of a geriatric screening and assessment in older patients with cancer in general oncology practice to date (n = 1967). The high inclusion rate in and outside the academic setting indicates that the implementation of a geriatric screening and assessment is very feasible. First of all, this study shows that the assessment has a major impact on the detection of unknown geriatric problems, geriatric interventions and treatment decisions. There are a few reports from single centres [6] [7] [8] where patients were generally treated by 'geriatric oncologists' in tertiary cancer centres focusing on geriatric oncology. The setting of the present study was different. Both academic and non-academic hospitals were included, broadening the scope of performing geriatric screening and assessment from dedicated geriatric oncology departments to general oncology practice. Also many specialists involved in the care of the older patient with cancer (surgeons, radiotherapists, medical oncologists, haematologists, urologists, gynaecologists etc.) were included, again bringing geriatric screening and assessment to the general oncology floor. So far, the vast majority of participating cancer specialists had rarely, if ever, been confronted with geriatric screening and assessment in their patients. The results of our questions concerning awareness of the assessment results at the time of treatment decision also indicate that about half of the treating physicians were not aware of the results of the assessment, although they were available in the medical file of the patient. As the study proceeded, awareness of the assessment results improved with statistical significance. There was only a small number (8%) of patients in whom the information requested by the questionnaire could not be obtained. This gives a unique insight in the thoughts and considerations of a large cohort of cancer specialists with regard to geriatric screening and assessment and its impact. Although, questionnaires are generally considered as burdensome and disturbing by physicians, this study suggests that physicians found the topic and the assessment information relevant enough to be willing to complete the questionnaire. This study also demonstrates that it is possible to bring 'geriatric oncology' towards general cancer specialists. Patients were cared for by their specialist, within the setting of standard oncology care, but had geriatric expertise provided through the geriatric screening and assessment. This contrasts with some other international attempts where specialized geriatric oncology units are being established. Although this is a worthwhile effort, it is unlikely that this kind of activities will reach large numbers of older Analysis only on cases where the physician was aware of the assessment results at the time of treatment decision. This included both patients with a normal score on the G8 (n = 316) and patients with an abnormal score on the G8 where screening was followed by CGA (n = 799). patients with cancer. Older patients are less likely to visit or to be referred to remote specialized centres. If frailty increases, it becomes more likely that they prefer being treated close to their homes. The organisation and implementation of geriatric screening and assessment for older patients with cancer in this study may be instrumental in providing a framework for application of geriatric screening and assessment in older patients with cancer. In this regard, it is worthwhile to mention that the Belgian government has launched a follow-up study of the current project, focusing on further implementation of geriatric screening and assessment in collaboration with the geriatricians in Belgium. Furthermore, one of the strengths of the current study is that in each of the 10 participating centres, a geriatrician, an oncologist and a trained health care worker were involved in the organization of the assessment. Oncologists can thus rely on geriatric expertise, mostly needed in patients in whom severe (unknown) problems are detected that require (geriatric) interventions. We should acknowledge that we were able to assess a large population, but that the results did not always reach the treating physician at the time of treatment decision, although this improved in time indicating that this study had an important sensibilisation aspect for the treating physicians. Nevertheless, further efforts are required to make (nongeriatric specialized) physicians familiar and sensitive to agerelated aspects not directly related to the tumour. Our prospective study confirms that the geriatric screening with G8 allows to identify about 29% of 'fit' patients who do not require a CGA before the treatment decision. It also confirms that 71% of older patients with cancer are in need for further assessment by CGA, which revealed more details about the underlying problems in a large proportion of patients (see Table 3 ). These data, as well as data from other studies, indicate that the majority of older patients with cancer have deficiencies in one or more geriatric domains, and that only a minority are perfectly fit. These 'fit' patients might not benefit from CGA and subsequent interventions, yet the information of 'fitness' can be important for the treating physician when making treatment decisions.
It is remarkable that in more than half of all the patients assessment revealed geriatric problems that were unknown to the treating physician. The problems were identified in all the domains assessed, and were present in >20% of patients for the domains of functionality, nutrition, fatigue, falls, depression and pain. This indicates the importance to address all these domains. In our study, 13.2% of the population have at least a mild cognitive impairment. This group is particularly at risk of delirium for example and deserves special attention. Moreover, the information of the assessment led to a geriatric intervention in 25.7% of patients if the treating physician was aware of the assessment results at the time of treatment decision. The gap between 51% of detected problems and 25% of planned interventions is probably partly due to some irreversible problems identified in this population (e.g. cognitive deficiencies, social issues etc.), but further implementation of geriatric screening and assessment in elderly oncology patients should focus on improving the intervention rate.
The present study does not allow for an in-depth analysis of the treatment decisions that were made based on the assessment. 'Influence' might be initiation of or abandoning a specific treatment, or a treatment alteration such as a dose reduction of chemotherapy, but it might also be that the treating physician was reassured by the results of the assessment when making a treatment decision.
A significant number of patients (n = 141) was evaluated with G8, when indicated followed by CGA, but were excluded from the study, mostly because they finally did not meet the inclusion criteria. The trained health care worker evaluated patients before a (final) treatment decision was taken. The exact medical information (progression or not, need for the treatment decision) was not always fully available when patients were approached. The identification of eligible patients was not always easy: several centres pre-screened all the multidisciplinary oncology boards or new patients on consultations, other centres only saw patients on physician or nurse request.
In conclusion, this current study showed that 71% of older patients with cancer benefit from a CGA but the revealed information does not always reach treating physicians. Efforts are needed to improve the interaction between oncologist, geriatrician and the trained health care worker. Our study also showed that geriatric screening and assessment were able to reveal unknown geriatric problems in more than half of the patients, and led to subsequent geriatric interventions in a quarter of patients. The detected problems and interventions occurred in all assessed domains. A standard clinical approach without assessment fails to evaluate all aspects of the older patient with cancer, and assessment has a substantial added value. Providing geriatric screening and assessment to a large population of older patients with cancer in collaboration with geriatricians is feasible in a routine clinical setting. It is beneficial to identify the older population 'fit enough' to tolerate optimal treatment-avoiding thus under-treatmentbut as important to detect 'frail' patients and not to over-treat these older patients with cancer at high risk of sometimes lifethreatening complications. Care for older patients with cancer can improve significantly by implementing geriatric screening and assessment in a systematic way in the health care system. acknowledgements
